Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain
Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...
Sino Medical Sciences Technology Secures Marketing Approval for Coronary Balloon Dilation Catheter in Morocco
Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...
Gan & Lee Pharmaceuticals Initiates Phase I Clinical Trial for Biosimilar Secukinumab
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...
Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy
Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...
Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...
NMPA’s Center for Drug Evaluation Issues New Guidelines for Domestic Transfer of Overseas-Produced Vaccines
The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the...
Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004
Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...
Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530),...
LINDIS Biotech’s Catumaxomab Receives Positive Opinion from EMA’s COMP for Malignant Ascites Treatment
LINDIS Biotech GmbH, a German biotechnology company, has announced that the Committee for Orphan Medicinal...
China’s NMPA Launches Pilot Program for Phased Manufacturing of Biological Products
The National Medical Products Administration (NMPA) has officially released the “Pilot Work Plan for Phased...
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...
China Grand Pharmaceutical Receives NMPA Approval for Innovative Adjustable Thrombectomy Stent
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has announced that it has...
Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...
Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines
The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP)...
Walvax Biotechnology’s Weuphoria Vaccine Approved in Oman for Pediatric Pneumococcal Infections
Walvax Biotechnology Co., Ltd (SHE: 300142), a Chinese biopharmaceutical company, has announced that it has...
German Endoscope Maker KARL STORZ Secures Marketing Approval for Disposable Ureteroscope in China
KARL STORZ SE & Co. KG, a leading German endoscope manufacturer, has announced that it...
LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review
LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...
Macrolux Raises Over RMB 100 Million in Series B Financing
Macrolux, a leading medical technology company specializing in disposable endoscopes, has announced the completion of...
AstraZeneca’s Wainzua Earns CHMP Nod for hATTR-PN Treatment in the EU
UK pharmaceutical juggernaut AstraZeneca (AZ, NASDAQ: AZN) has announced that Wainzua (eplontersen), an RNA-targeted therapy...
Novo Nordisk’s Semaglutide Shows 14% Reduction in Cardiovascular Events in Landmark SOUL Trial
Copenhagen-based healthcare giant Novo Nordisk (NYSE: NVO) has declared the primary outcomes of the SOUL...